

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/apm-20-430	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared, and we also found a significant correlation was observed between the SHP2 and Hook1 expression in NSCLC patients. SHP2 was an independent indicator for overall survival and patients with negative SHP2 expression could benefit from gemcitabine plus carboplatin chemotherapy.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists and clinical pharmacists who are interested in studies of molecular markers.
8	For what type of analysis or purpose?	For analysis to evaluate the predictive value of SHP2 and Hook1 in NSCLC.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: linrunw@zju.edu.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.